Pop.. And there goes 4c.. Now 3.9
To state the obvious, this is not good.... How does a company with a drug in active clinical trials have such a low market cap?
What has management said or done that has seemed to have discouraged anyone from investing here. Seems all their pre clinical work and past 'successes' seem to mean squat to the market
Was anyone here able to listen in to the agm and ask some of these questions?
Ann: 2018 AGM Presentation, page-9
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
